(Q36927353)

17 August 2017

1 reference

title

Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check (English)

1 reference

17 August 2017

1 reference

0 references

1 reference

1 reference

Kathleen Seitz

1

1 reference

17 August 2017

Honghui Zhou

series ordinal

2

1 reference

17 August 2017

publication date

1 September 2007

1 reference

The Journal of Clinical Pharmacology

17 August 2017

published in

1 reference

17 August 2017

volume

47

1 reference

17 August 2017

issue

9

1 reference

17 August 2017

page(s)

1104-1118

1 reference

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Development and regulation of monoclonal antibody products: challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpres

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Disposition of paclitaxel (Taxol) and its metabolites in patients with advanced breast cancer (ABC) when combined with trastuzumab (Hercpetin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Elimination mechanisms of therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Regulation of drug metabolism and disposition during inflammation and infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

"Cocktail" approaches and strategies in drug development: valuable tool or flawed science?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

Drug interaction between infliximab and azathioprine in patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007306958

21 January 2018

Identifiers

DOI

10.1177/0091270007306958

1 reference

17 August 2017

1 reference